Pre-exposure prophylaxis (PrEP) for HIV-negative people, based on emtricitabine and tenofovir disoproxil, has recently obtained reimbursement. This was established by the Italian Medicines Agency (Aifa) at the request of Mylan Pharmaceuticals Limited. This was discussed at the press conference held by the Viatris group, of which Mylan is a part, dedicated to the issues of preventing the spread of HIV infection. Andrea Gori, member of the Infectious Diseases department of the Luigi Sacco hospital, professor at the University of Milan and president of the Lombard section of the National Association for the fight against AIDS (Anlaids Onlus) spoke on this occasion.
#PrEP #Hiv #Gori #Sacco #hospital #Reimbursability #largescale #prevention